Tuesday, August 30, 2016

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave

* Orexigen Therapeutics announces commercialization and

distributorship agreement with Valeant Canada for Contrave

(naltrexone hcl / bupropion hcl extended release)

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)